216 related articles for article (PubMed ID: 8694533)
1. Clinical applications of urinary gonadotropin peptides (UGP) in gynecologic oncology.
Schwartz PE; Cracchiolo BM; Cole LA
Anticancer Res; 1996; 16(4B):2135-9. PubMed ID: 8694533
[TBL] [Abstract][Full Text] [Related]
2. Beta-core fragment (beta-core/UGF/UGP), a tumor marker: a 7-year report.
Cole LA; Tanaka A; Kim GS; Park SY; Koh MW; Schwartz PE; Chambers JT; Nam JH
Gynecol Oncol; 1996 Feb; 60(2):264-70. PubMed ID: 8631549
[TBL] [Abstract][Full Text] [Related]
3. Urinary gonadotropin peptide (UGP) and serum CA 125 in gynaecologic practice, a clinical prospective study.
Schutter EM; Mijatovic V; Kok A; Van Kamp GJ; Verstraeten R; Verheijen RH
Anticancer Res; 1999; 19(6C):5551-7. PubMed ID: 10697615
[TBL] [Abstract][Full Text] [Related]
4. UGP--a tumor marker of gynecologic and breast malignancies? Specificity and sensitivity in pretherapeutic patients and the influence of hormonal substitution on the expression of UGP.
Schwarz-Roeger U; Petzoldt B; Waldschmidt R; Walker RP; Bauknecht T; Kiechle M
Anticancer Res; 1997; 17(4B):3041-5. PubMed ID: 9329597
[TBL] [Abstract][Full Text] [Related]
5. Urinary human chorionic gonadotropin free beta-subunit and beta-core fragment: a new marker of gynecological cancers.
Cole LA; Wang YX; Elliott M; Latif M; Chambers JT; Chambers SK; Schwartz PE
Cancer Res; 1988 Mar; 48(5):1356-60. PubMed ID: 3342414
[TBL] [Abstract][Full Text] [Related]
6. Urinary gonadotropin peptide (UGP) as a marker of gynecologic malignancies.
Walker R; Crebbin V; Stern J; Scudder S; Schwartz P
Anticancer Res; 1994; 14(5A):1703-9. PubMed ID: 7847804
[TBL] [Abstract][Full Text] [Related]
7. The beta-core fragment of human chorionic gonadotropin: biochemical background and clinical application.
Schutter EM; Mulder C; van Kamp GJ; Kenemans P
Anticancer Res; 1997; 17(2B):1255-72. PubMed ID: 9137483
[TBL] [Abstract][Full Text] [Related]
8. UGP in urogenital disorders: Egyptian experience.
el-Ahmady O; Halim AB; Gad M; Walker R
Anticancer Res; 1996; 16(4B):2301-8. PubMed ID: 8694560
[TBL] [Abstract][Full Text] [Related]
9. Combined use of urinary UGP and serum CA 125 in the diagnosis of gynecological cancers.
Plebani M; Navaglia F; Basso D; De Paoli M; Nicoletto MO; Maraglino E; Torre GC
Anticancer Res; 1996; 16(6B):3833-8. PubMed ID: 9042266
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic significance of tumor markers for gynecologic malignancies].
Aoki D; Hirasawa A; Susumu N
Gan To Kagaku Ryoho; 2005 Mar; 32(3):411-6. PubMed ID: 15791829
[TBL] [Abstract][Full Text] [Related]
11. Chronobiologic aspects of urinary gonadotropin peptide (UGP).
Cornélissen G; Halberg F; Walker R; Zaslavskaya RM; Fine RL; Haus E
In Vivo; 1995; 9(4):359-62. PubMed ID: 8555435
[TBL] [Abstract][Full Text] [Related]
12. [Development of highly sensitive enzyme immunoassay to measure urinary beta-core fragment in patients with gynecological cancer].
Nishimura R; Kobayashi K; Katsuno M; Kobayashi T
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Feb; 42(2):143-8. PubMed ID: 1690253
[TBL] [Abstract][Full Text] [Related]
13. The prognostic significance of urinary beta core fragment in premenopausal women with carcinoma of the cervix.
Carter PG; Iles RK; Neven P; Ind TE; Shepherd JH; Chard T
Gynecol Oncol; 1994 Nov; 55(2):271-6. PubMed ID: 7525427
[TBL] [Abstract][Full Text] [Related]
14. Role of PET in gynecologic malignancy.
Grigsby PW
Curr Opin Oncol; 2009 Sep; 21(5):420-4. PubMed ID: 19553814
[TBL] [Abstract][Full Text] [Related]
15. Gynecologic malignancies.
Whitcomb BP
Surg Clin North Am; 2008 Apr; 88(2):301-17, vi. PubMed ID: 18381115
[TBL] [Abstract][Full Text] [Related]
16. [Human chorionic gonadotropin beta-core fragment (hCG beta-cf)].
Okamoto T
Nihon Rinsho; 1999 Dec; 57 Suppl():586-8. PubMed ID: 10778198
[No Abstract] [Full Text] [Related]
17. The quagmire of hCG and hCG testing in gynecologic oncology.
Muller CY; Cole LA
Gynecol Oncol; 2009 Mar; 112(3):663-72. PubMed ID: 19007977
[TBL] [Abstract][Full Text] [Related]
18. Urinary gonadotropin fragment, a new tumor marker. III. Use in cervical and vulvar cancers.
Nam JH; Chang KC; Chambers JT; Schwartz PE; Cole LA
Gynecol Oncol; 1990 Jul; 38(1):66-70. PubMed ID: 2354828
[TBL] [Abstract][Full Text] [Related]
19. Gynecologic cancers.
Blair AR; Casas CM
Prim Care; 2009 Mar; 36(1):115-30, ix. PubMed ID: 19231605
[TBL] [Abstract][Full Text] [Related]
20. Knowledge of tumor markers and the psychological consequences of tumor marker sampling in patients with gynecologic cancers.
Mayerhofer K; Bodner K; Aktas C; Schindl M; Kaider A; Leodolter S; Joura EA; Kainz C
Anticancer Res; 2000; 20(2B):1281-4. PubMed ID: 10810435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
